Sequential loss of LC noradrenergic and dopaminergic neurons results in a correlation of dopaminergic neuronal number to striatal dopamine concentration

Frontiers in Pharmacology

Volumn 3 OCT, Issue , 2012, Pages

  Szot, Patricia ^a,b   Franklin, Allyn ^a   Sikkema, Carl ^c   Wilkinson, Charles W ^b,c   Raskind, Murray A ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Veteran's Administration Puget Sound Health Care System   (United States)

Author keywords

6 hydroxydopamine; Catecholamines; Locus coeruleus; MPTP; Striatum; Substantia nigra; Ventral tegmentum area

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; CATECHOLAMINE; DOPAMINE; NORADRENALIN; NORADRENALIN TRANSPORTER; OXIDOPAMINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN REGION; CELL COUNT; CELL LOSS; CONTROLLED STUDY; CORRELATIONAL STUDY; DOPAMINERGIC NERVE CELL; LIQUID CHROMATOGRAPHY; LOCUS CERULEUS; MALE; MOUSE; NERVE INJURY; NONHUMAN; NORADRENERGIC NERVE; STRIATE CORTEX; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

EID: 84870737461     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00184     Document Type: Article

References (78)

1. Alexander, G. M., Schwartzman, R. J., Brainard, L., Gordon, S. W., and Grothusen, J. R. (1992). Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys. Brain Res. 588, 261-269.
2. Antelman, J. E., and Caggiula, A. R. (1977). Norepinephrinedopamine interaction and behavior. Science 195, 646-653.
3. Archer, T., and Fredriksson, A. (2006). Influence of noradrenaline denervation on MPTP-induced deficits in mice. J. Neural Transm. 113, 1119-1129.
4. Arencibia-Albite, F., Paladini, C., Williams, J. T., and Jimenez-Rivera, C. A. (2007). Noradrenergic modulation of the hyperpolarizationactivated cation current (Ih) in dopamine neurons of the ventral tegmental area. Neuroscience 149, 303-314.
5. Barnum, C. J., Bhide, N., Lindenbach, D., Surrena, M. A., Goldenberg, A. A., Tignor, S., et al. (2012). Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α-and β-adrenergic receptor antagonists in hemiparkin-sonian rats. Pharmacol. Biochem. Behav. 100, 607-615.
6. Bertrand, E., Lechowicz, W., Szpak, G. M., and Dynecki, J. (1997). Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease. Folia Neuropathol. 35, 80-86.
7. Bezard, E., Dovero, S., Imbert, C., Boraud, T., and Gross, C. E. (2000). Spontaneous longterm compensatory dopaminergic sprouting in MPTP-treated mice. Synapse 38, 363-368.
8. Bing, G., Zhang, Y., Watanabe, Y., McEwen, B. S., and Stone, E. A. (1994). Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res. 668, 261-265.
9. Booze, R. M., Hall, J. A., Cress, N. M., Miller, G. D., and Davis, J. N. (1988). DSP-4 treatment produces abnormal tyrosine hydroxylase immunoreactive fibers in rat hippocampus. Exp. Neurol. 101, 75-86.
10. Braak, H., Rub, U., Gai, W. P., and Tredici, K. D. (2006). Cognitive decline correlates with neuropathological stage in Parkinson's disease. J. Neurol. Sci. 248, 255-258.
11. Braak, H., Tredici, K. D., Rub, U., de Vos, R. A. I., Jansen Steur, E. N. H., and Braak, A. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211.
12. Cash,R.,Dennis,T.,L'Heureux,R.,Raisman, R., Javoy-Agid, F., and Scatton, B. (1987). Parkinson's disease and dementia: norepinephrine and dopamine in locus coeruleus. Neurology 37, 42-46.
13. Chan-Palay, V., and Asan, E. (1989). Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer's type and in Parkinson's disease with and without dementia and depression. J. Comp. Neurol. 287, 373-392.
14. Chopin, P., Colpaert, F. C., and Marien, M. (1999). Effects of alpha-2-adrenoreceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J. Pharmacol. Exp. Ther. 288, 798-804.
15. Damier, P., Hirsch, E. C., Agrid, Y., and Graybiel, A. M. (1999). The substantia nigra of the human brain. II. Patterns of loss of dopaminergic neurons in Parkinson'sdisease. Brain 122, 11437-11448.
16. Donnan, G. A., Kaczmarczyk, S. J., Solopotias, T., Rowe, P., Kalnins, R. M., Vajda, F. J., et al. (1986). The neurochemical and clinical effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in small animals. Clin. Exp. Neurol. 22, 155-164.
17. Fornai, F., Alessandri, M. G., Torracca, M. T., Bassi, L., and Corsini, G. U. (1997). Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions. J. Pharmacol. Exp. Ther. 283, 100-107.
18. Fornai, F., Bassi, L., Torracca, M. T., Scalori, V., and Corsini, G. U. (1995). Norepinephrine loss exacerbates methamphetamineinduced striatal dopamine depletion in mice. Eur. J. Pharmacol. 283, 99-102.
19. Fornai, F., Torracca, M. T., Bassi, L., D'Errigo, D. A., Scalori, V., and Corsini, G. U. (1996). Norepinephrine loss selectively enhances chronic nigrostriatal dopamine depletion in mice and rats. Brain Res. 735, 349-353.
20. Fritschy, J. M., and Grzanna, R. (1990). Distribution of locus coeruleus axons within the rat brainstem demonstrated by Phaseolus vulgaris leucoagglutinin anterograde tracing in combination with dopamine-β-hydroxylase immunofluorescence. J. Comp. Neurol. 293, 616-631.
21. Gibb, W. R. G. (1991). Neuropathology of the substantia nigra. Eur. Neurol. 31(Suppl.), 48-59.
22. Gibb, W. R. G., and Lees, A. J. (1991). Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 54, 388-396.
23. Goldstein, D. S., Feuerstein, G., Izzo, J. L. Jr., Kopin, I. J., and Keiser, H. R. (1981). Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci. 28, 467-475.
24. Grenhoff, J., Nissel, M., Aston-Jones, G., and Svensson, T. H. (1993). Noradrenergic modulation of mid-brain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J. Neural Transm. 93, 11-25.
25. Grenhoff, J., North, R. A., and Johnson, S. W. (1995). Alpha1-adrenrgic effects on dopamine neurons recorded intracellularly in the rat midbrain slice. Eur. J. Neurosci. 7, 1707-1713.
26. Grenhoff, J., and Svensson, T. H. (1989). Clonidine modulates dopamine cell firing in rat ventral tegmental area. Eur. J. Pharmacol. 165, 11-18.
27. Grenhoff, J., and Svensson, T. H. (1993). Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. Eur. J. Pharmacol. 233, 79-84.
28. Grima, B., Lamouroux, A., Blanot, F., Biguet, N. F., and Mallet, J. (1985). Complete coding sequence of rat tyrosine hydroxylase mRNA. Proc. Natl. Acad. Sci. U.S.A. 82, 617-621.
29. Grimbergen, Y. A. M., Langston, J. W., Roos, R. A. C., and Bloem, B. (2009). Postural instability in Parkinson's disease: the adrenergic hypothesis and locus coeruleus. Expert Rev. Neurother. 9, 279-290.
30. Grzanna, R., Berger, U., Fritschy, J.-M., and Geffard,M. (1989). Acute action of DSP-4 on central norepinephrine axons: biochemical and immunohistochemical evidence for differential effects. J. Histochem. Cytochem. 37, 1435-1442.
31. Guiard, B. P., Mansari, M. E., Merali, Z., and Blier,P. (2008). Functional interactions between dopamine, serotonin and norepinephrine neurons: an invivo electrophysiological study in rats with monoaminergic lesions. Int. J. Neuropsychopharmacol. 11, 625-639.
32. Heikkila, R. E., Hess, A., and Duvoisin, R. C. (1984). Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224, 1451-1453.
33. Hornykiewicz, O., and Kish, S. J. (1987). Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45, 19-34.
34. Hughes, Z. A., and Stanford, S. C. (1998). A partial noradrenergic lesion induced by DSP4 increases extracellular noradrenaline concentration in rat frontal cortex: a microdialysis study in vivo. Psychopharmacology (Berl.) 136, 299-303.
35. Jackson-Lewis, V., Jakowec, M., Burke, R. E., and Przedborski, S. (1995). Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4, 257-269.
36. Jakowec, M. W., Nixon, K., Hogg, E., McNeill, T., and Petzinger, G. M. (2004). Tyrosine hydroxylase and dopamine transporter expression and following 1-methyl-4-pheyl-1,2,3,6-tetrahydropyridineinduced neurodegeneration of the mouse nigrostriatal pathway. J. Neurosci. Res. 76, 539-550.
37. Javoy-Agid, F., Hirsch, E. C., Dumas, S., Duyckaerts, C., Mallet, J., and Agid, Y. (1990). Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study. Neuroscience 38, 245-253.
38. Jones, B. E., and Moore, R. Y. (1977). Ascending projections of the locus coeruleus in the rat. II. Autoradiographic study. Brain Res. 127, 23-53.
39. Jones, B. E., and Yang, T. Z. (1985). The efferent projections from the reticular formation and the locus coeruleus studied by anterograde and retrograde axonal transport in the rat. J. Comp. Neurol. 242, 56-92.
40. Jonsson, G., Hallman, H., Ponzio, F., and Ross, S. (1981). DSP4 (N-(2-chloroethyl)-Nethyl-2- bromobenzylamine)-a useful denervation tool for central and peripheral noradrenaline neurons. Eur. J. Pharmacol. 72, 173-188.
41. Kask, A., Harro, J., Tuomainen, P., Rago, L., and Mannisto, P. T. (1997). Overflow of noradrenaline and dopamine in frontal cortex after [N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine] (DSP-4) treatment: in vivo microdialysis study in anaesthetized rats. Naunyn Schmiedebergs Arch. Pharmacol. 355, 267-272.
42. Kastner, A., Hirsch, E. C., Herrero, M. T., Javoy-Agid, F., and Agid, Y. (1993). Immunocytochemical quantification of tyrosine hydroxylase in the mesencephalon of control subjects and patients with Parkinson's and Alzheimer's disease. J. Neurochem. 61, 1024-1034.
43. Lategan, A. J., Marien, M. R., and Colpaert, F. C. (1990). Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis. Brain Res. 523, 134-138.
44. Lategan, A. J., Marien, M. R., and Colpaert, F. C. (1992). Suppression of nigrostriatal and mesolimbic release in vivo following noradrenaline depletion by DSP-4: a microdialysis study. Life Sci. 50, 995-999.
45. Lyons, W. E., Fritschy, J. M., and Grzanna, R. (1989). The noradrenergic neurotoxin DSP-4 eliminates the coeruleospinal projection but spares projections of the A5 and A7 groups to the ventral horn of the rat spinal cord. J. Neurosci. 9, 1481-1489.
46. MacRae-Degueurce, A., and Milon, H. (1983). Serotonin and dopamine afferents to the rat locus coeruleus: a biochemical study after lesioning of the ventral mesencephalic tegmental-A10 region and the raphe dorsalis. Brain Res. 263, 344-347.
47. Marien, M., Briley, M., and Colpaert, F. (1993). Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur. J. Pharmacol. 236, 487-489.
48. Matsukawa, M., Nakadate, K., Ishihara, I., and Okado, N. (2003). Synaptic loss following depletion of noradrenaline and/or serotonin in the rat visual cortex: a quantitative electron microscopic study. Neuroscience 122, 627-635.
49. Mavridis, M., Degryse, A.-D., Lategan, A. J., Marien, A. J., and Colpaert, F. C. (1991). Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 41, 507-523.
50. McMahon, A., Geertman, R., and Sabban, E. L. (1990). Rat dopamine β-hydroxylase: molecular cloning and characterization of the cDNA and regulation of the mRNA by reserpine. J. Neurosci. Res. 25, 395-404.
51. McMillan, P. J., White, S. S., Franklin, A., Greenup, J. L., Leverenz, J. B., Raskind, M. A., et al. (2011). Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease. Brain Res. 1373, 240-252.
52. Miguelez, C., Grandoso, L., and Ugedo, L. (2011). Locus coeruleus and dorsal raphe neuron activity and response to acute antidepressant administration in a rat model of Parkinson's disease. Int. J. Neuropsychopharmacol. 14, 187-200.
53. Nagatsu, T., and Sawada, M. (2007). Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J. Neural Transm. Suppl. 72, 113-120.
54. Patt, S., and Gerhard, L. (1993). A golgi study of human locus coeruleus in normal brains and in Parkinson's disease. Neuropathol. Appl. Neurobiol. 19, 519-523.
55. Perry, T. L., Yong, V. W., Jones, K., Wall, R. A., Clavier, R. M., Foulks, J. G., et al. (1985). Effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its metabolite, N-methyl-4-phenylpyridinium ion, on dopaminergic nigrostriatal neurons in the mouse. Neurosci. Lett. 58, 321-326.
56. Phillipson, O. T. (1979). Afferent projections to the ventral tegmental area of Tsai and interfascicular nucleus: a horseradish peroxidase study in the rat. J. Comp. Neurol. 187, 117-144.
57. Ricaurte, G. A., Langston, J. W., DeLanney, L. E., Irwin, I., Peroutka, S. J., and Forno, L. S. (1986). Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res. 376, 117-124.
58. Robertson, G. B., Fluharty, S. J., Zigmond, M. J., Sclabassi, R. J., and Berger, T. W. (1993). Recovery of hippocampal dentate gyrus granule cell responsiveness to entorhinal cortical input following norepinephrine depletion. Brain Res. 61, 21-28.
59. Rommelfanger, K. S., Edwards, G. L., Freeman, K. G., Liles, L. C., Miller, G. W., and Weinshenker, D. (2007). Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc. Natl. Acad. Sci. U.S.A. 104, 13804-13809.
60. Rommelfanger, K. S., and Weinshenker, D. (2007). Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem. Pharmacol. 74, 177-190.
61. Ross, S. B. (1976). Longterm effects of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurons in the rat brain and heart. Br. J. Pharmacol. 58, 521-527.
62. Sanders, J. D., Szot, P., Weinshenker, D., Happe, H. K., Bylund, D. B., and Murrin, L. C. (2006). Analysis of brain adrenergic receptors in dopamine-β-hydroxylase knockout mice. Brain Res. 1109, 45-53.
63. Simon, H., Le Moal, M., and Calas, A. (1979). Efferents and afferents of the ventral tegmental=A10 region studied after local injection of [3H]leucine and horseradish peroxidase. Brain Res. 178, 17-40.
64. Singh, N., Pillay, V., and Choonara, Y. E. (2007). Advances in the treatment of Parkinson's disease. Prog. Neurobiol. 81, 29-44.
65. Srinivasan, J., and Schmidt, W. J. (2003). Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamineinduced partial degeneration of substantia nigra in rats. Eur. J. Pharmacol. 17, 2586-2592.
66. Srinivasan, J., and Schmidt, W. J. (2004). Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamineinduced rat model of Parkinson's disease. Behav. Brain Res. 151, 191-199.
67. Swanson, L. W., and Hartman, B. K. (1975). The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-β-hydroxylase as a marker. J. Comp. Neurol. 163, 467-505.
68. Szot, P., Knight, L., Franklin, A., Sikkema, C., Foster, S., Wilkinson, C. W., et al. (2012). Lesioning noradrenergic neurons of the locus coeruleus in C57Bl/6 mice with unilateral 6-hydroxydopamine injection, to assess molecular, electrophysiological and biochemical changes in noradrenergic signaling. Neuroscience 216, 143-157.
69. Szot, P., Miguelez, C., White, S. S., Franklin,A.,Sikkema,C.,Wilkinson, C. W., et al. (2010). A comprehensive analysis of the effect of DSP4 on the locus coeruleus noradrenergic system in the rat. Neuroscience 166, 279-291.
70. Szot, P., White, S. S., Greenup, J. L., Leverenz, J. B., Peskind, E. R., and Raskind, M. A. (2006). Compensatory changes in the noradrenergic nervous system in the locus coeruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J. Neurosci. 26, 467-478.
71. Szot, P., White, S. S., and Veith, R. C. (1997). Effect of pentylenetetrazol on the expression of tyrosine hydroxylase mRNA and norepinephrine and dopamine transporter mRNA. Brain Res. Mol. Brain Res. 44, 46-54.
72. Taylor, T. N., Caudle, W. M., Sheperd, K. R., Noorian, A., Jackson, C. R., Iuvone, P. M., et al. (2009). Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci. 29, 8103-8113.
73. Theron, C. N., de Villiers, A. S., and Taljaard, J. J. (1993). Effects of DSP-4 on monoamine and monoamine metabolites levels and on beta adrenoreceptor binding kinetics in rat brain at different times after administration. Neurochem. Res. 18, 1321-1327.
74. Thomas, S. A., Marck, B. T., Palmiter, R. D., and Matsumoto, A. (1998). Restoration of norepinephrine and reversal of phenotypes in mice lacking dopamine-β-hydroxylase. J. Neurochem. 70, 2468-2476.
75. Wang, Y., Zhang, Q. J., Liu, J., Ali, U., Gui, Z. H., Hui, Y. P., et al. (2010). Noradrenergic lesion of the locus coeruleus increases apomorphineinduced circling behavior and the firing activity of substantia nigra pars reticulata neurons in a rat model of Parkinson's disease. Brain Res. 1310, 189-199.
76. Weinshenker, D., White, S. S, Javors, M. A., Palmiter, R. D., and Szot, P. (2002). Regulation of norepinephrine transporter abundance by catecholamines and desipramine in vivo. Brain Res. 946, 239-246.
77. Wolfman, C., Abo, V., Calvo, D., Medina, J., Dajas, F., and Silveiro, R. (1994). Recovery of central noradrenergic neurons one year after the administration of the neurotoxin DSP4. Neurochem. Int. 25, 395-400.
78. Zarow, C., Lyness, S. A., Mortimer, J. A., and Chui, H. C.(2003). Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer' and Parkinson disease. Arch. Neurol. 60, 337-341.